Dr. Inger Sandlie is professor at the Department of Biosciences, University of Oslo and a research group leader at the Department of Immunology, Oslo University Hospital. She is also deputy director of the Centre for Immune Regulation, which aims to identify and investigate novel mechanisms of immune dysregulation that contribute to
autoimmune and allergic disease, and to advance the development of therapeutics. Her research group studies the structure and function of albumin as well as antibodies and T-cell receptors, and engineers these molecules for use as therapeutics and research tools. She has co-authored more than 100 publications since 1990, and has received awards for scientific innovation. Sandlie is inventor on numerous patents and is co-founder of two biotechnology companies, Vaccibody and Nextera.